Current Neurology and Neuroscience Reports

, Volume 9, Issue 5, pp 384-389

Current pharmacologic testing for horner syndrome

  • Mansoor Mughal
  • , Reid LongmuirAffiliated withDepartment of Ophthalmology and Visual Sciences, The University of Iowa Hospitals and Clinics Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


First described in 1727, Horner syndrome occurs from injury to one of the three neurons in the oculo-sympathetic pathway. Its presence can be confirmed with pharmacologic testing, traditionally including cocaine testing with hydroxyamphetamine localization. More recently, apraclonidine testing has become a viable alternative in some practices. Concern has been raised regarding the possibility of false-negative results with apraclonidine testing as well as the safety of its use in young children.